IOP:n laskun vaikutus progressiiviseen HM:ään (PHM)
Lääketieteellisen silmänsisäisen paineen alentamisen vaikutus progressiiviseen korkeaan likinäköisyyteen
Currently, whether and when intraocular pressure (IOP) lowering medication should be used in progressive high myopia (HM) to control axial elongation is still a dilemma. Randomized trials are required to evaluate whether IOP lowering influences the growth of axial length in progressive HM eyes.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
Myopia has emerged as a major health issue in east Asia, especially the sight-threatening complications associated with high myopia (HM). Complication of HM can be associated with significant ocular morbidities including maculopathy, retinal detachment, and glaucoma.
Previous studies have shown that adult patients with HM have sustained growth of the axial length (AL), which is a risk factor for the progression of pathological myopia and thus may further affect the visual function , so how to slow down the sustained growth of the AL in adult patients with HM has become an urgent clinical problem. Previous studies have shown that IOP-lowering treatment is a protective factor for the growth of the AL in HM , and the results of animal experiments have further shown that medically IOP-lowering treatment can significantly slow down the AL lengthening and refractive changes in the guinea pig model of myopia. On this basis, the investigators proposed in a previous article that medically IOP-lowering treatment may slow down the growth of AL by three pathways related to the sclera and choroid: for the sclera, IOP-lowering treatment may reduce the scleral distending force, slow down the rate of scleral distension, and inhibit the activation of scleral fibroblasts to reduce scleral remodeling; for the choroid, IOP-lowering treatment may increase choroidal blood perfusion and for the choroid, hypotensive treatment can increase choroidal perfusion and thus reduce scleral remodeling due to scleral hypoxia. A previous retrospective study conducted by the investigators also shows that medically IOP-lowering treatment could control the progression of AL in HM, but there is still a lack of evidence from relevant robust randomized controlled clinical trials (RCT).
The investigators propose to conduct a RCT to evaluate whether medically IOP-lowering therapy is effective in controlling the progression of AL in HM. Secondly, this study also aims to provide data to evaluate IOP-lowering treatment effects on the incidence of changes in the visual field (VF), optic nerve head morphology including the retinal nerve fiber layer (RNFL), and retinal ganglion cell-inner plexiform layer (GC-IPL) loss, progression of myopic maculopathy, loss in visual function and change in quality of life. The outcomes of this study may provide a strong basis for treatment recommendations to control the progression of high myopic eyes, and to provide high-quality clinical research evidence for international clinical guidelines on myopia.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Guangdong
-
Guangzhou, Guangdong, Kiina, 510060
- Zhongshan Ophthalmic Center, Sun Yat-sen University
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Informed consent given, and consent form signed.
- Age between 18 and 65 years.
- Diagnosed with HM: spherical equivalent ≤ -6.00 diopters or AL ≥ 26.5 mm.
- Progressive HM: progression in AL ≥0.05mm in the past 6 months or ≥0.1mm in the past 12 months.
- IOP ≥ 10 mmHg and ≤ 21mmHg on at least 2 visits, as measured by Goldmann applanation tonometry .
- Best corrected visual acuity (BCVA) ≥ 6/12, and being able to obtain adequate AL examination, fundus photographs, optical coherence tomography (OCT) and complete the VF examination.
Exclusion Criteria:
- Allergic to any kind of IOP-lowering therapy.
- Combination of various serious fundus pathologies, such as proliferative diabetic retinopathy, retinal detachment, central retinal artery occlusion, etc.
- Combination of chronic, recurrent or severe ocular inflammatory lesions, such as chronic or recurrent uveitis.
- Patients with significant corneal or iris lesions, or severe cataract affecting fundus examination, or patients with only one eye.
- Patients who have undergone any surgery or laser treatment affecting eye parameters during the follow-up period (within the last 1 year), such as cataract surgery.
- Patients with other serious systemic diseases, such as hypertension, heart disease, diabetes, rheumatic immune system disease, etc., who cannot tolerate long-term follow-up and eye treatment.
- Pregnant or lactating women, or those who plan to have children during the follow-up period.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Yksittäinen
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: Intervention arm
medical reduction of IOP by eyedrops |
IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the choice for treatment. |
|
Ei väliintuloa: control arm
follow up without medication |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Annualized change in axial length (AL) from baseline to 12 months
Aikaikkuna: 12 months
|
The cumulative change in AL from baseline to 12 months. |
12 months
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Annualized change in axial length (AL) from baseline to 24 months
Aikaikkuna: 24 months
|
The cumulative change in AL from baseline to 24 months divided by 2 years. |
24 months
|
|
Annualized change in axial length (AL) from baseline to 36 months
Aikaikkuna: 36 months
|
The cumulative change in AL from baseline to 36 months divided by 3 years. |
36 months
|
|
Change in spherical equivalent (SE) from baseline
Aikaikkuna: 12, 24, and 36 months
|
Change in spherical equivalent refraction (SE) from baseline. |
12, 24, and 36 months
|
|
Change in intraocular pressure (IOP) from baseline
Aikaikkuna: 12, 24, and 36 months
|
Change in intraocular pressure (IOP) from baseline |
12, 24, and 36 months
|
|
Change in choroidal thickness (ChT) from baseline
Aikaikkuna: 12, 24, and 36 months
|
Change in subfoveal choroidal thickness (ChT) measured by OCT from baseline. |
12, 24, and 36 months
|
|
Change in visual field (VF) parameters and incidence/progression of VF defects
Aikaikkuna: 12, 24, and 36 months
|
Change in Humphrey 24-2 mean deviation (MD) and pattern standard deviation (PSD) from baseline, and the incidence and progression of visual field defects |
12, 24, and 36 months
|
|
Change in retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) thickness
Aikaikkuna: 12, 24, and 36 months
|
Change in peripapillary RNFL and macular GCIPL thickness measured by OCT from baseline |
12, 24, and 36 months
|
|
Change in retinal and choroidal vascular parameters measured by OCTA
Aikaikkuna: 12, 24, and 36 months
|
Change in vessel density of the superficial capillary plexus (SCP) and deep capillary plexus (DCP), and choriocapillaris (CC) flow metrics from baseline |
12, 24, and 36 months
|
|
Incidence of optic nerve head morphological changes
Aikaikkuna: 12, 24, and 36 months
|
Incidence of morphological changes based on stereoscopic fundus photography, including increased cup-to-disc ratio, neuroretinal rim notching, wedge-shaped RNFL defects, or disc hemorrhage. |
12, 24, and 36 months
|
|
Incidence and progression of myopic maculopathy (MMD)
Aikaikkuna: 12, 24, and 36 months
|
The incidence and progression rate of myopic maculopathy classified by the international photographic classification system. |
12, 24, and 36 months
|
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Aikaikkuna: 1 month, 3 month, 6 month, 12 month, 24 month, 36 month
|
The incidence, severity, and relationship to study medication of all adverse events (AEs) and serious adverse events (SAEs) |
1 month, 3 month, 6 month, 12 month, 24 month, 36 month
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Tutkijat
Tutkijat
- Päätutkija: Xiulan Zhang, MD, PhD, Sun Yat-sen University
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Leske MC, Heijl A, Hyman L, Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999 Nov;106(11):2144-53. doi: 10.1016/s0161-6420(99)90497-9.
- Leske MC, Hyman L, Hussein M, Heijl A, Bengtsson B. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1999 May;127(5):625-6. No abstract available.
- Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald RP, Xing W, Zeyen TG. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015 Apr 4;385(9975):1295-304. doi: 10.1016/S0140-6736(14)62111-5. Epub 2014 Dec 19.
- Jiang J, Lin T, Lin F, Kong K, Wang P, Song Y, Zhou F, Wang Z, Jin L, Liu Y, Gao X, Chen J, Chen M, Lam DSC, Jonas JB, Chen S, Zhang X; Glaucoma Suspects with High Myopia Study Group. Effect of intraocular pressure reduction on progressive high myopia (PHM study): study protocol of a randomised controlled trial. BMJ Open. 2024 Jun 5;14(6):e084068. doi: 10.1136/bmjopen-2024-084068.
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- 2023KYPJ110
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .